A Phase I/II Study of ABT-888 in Combination with 5-Fluorouracil and Oxaliplatin (modified FOLFOX6) in Patients with Metastatic Pancreatic Cancer.
People are being asked to participate in this study who have metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxaliplatin) for patients with metastatic pancreatic cancer. ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the mFOLFOX-6, and will hopefully increase the killing of cancer cells, thus decreasing the tumors in your body. ABT-888 is an investigational or experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration (FDA) for use in pancreatic cancer.
A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients with Metastatic Pancreatic Cancer.
The purpose of this study is to evaluate the clinical activity of the combination of gemcitabine and nab-paclitaxel as second line treatment in patients with metastatic pancreatic cancer who have received non-gemcitabine-based chemotherapy in the first line setting.
JANUS 2: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy
The purpose of this study is to find out if the study drug ruxolitinib phosphate also known as Jakafi® or INCB018424 (called ruxolitinib from here on) is effective and safe in combination with a chemotherapy medicine called capecitabine or Xeloda® (called capecitabine from here on). This study will test if this combination has beneficial effects in people diagnosed with pancreatic cancer that cannot be treated by surgery or has spread to other parts of the body and who have failed one treatment of chemotherapy for this condition.
The primary goal of this study is to determine how long subjects with pancreatic cancer live after receiving treatment with capecitabine and ruxolitinib compared with those who receive treatment with capecitabine alone. The other aims of this study are to determine:
- Whether ruxolitinib when added to capecitabine causes your tumor(s) to shrink or stop growing and if this will prolong the time to the cancer worsening.
- If ruxolitinib when given with capecitabine can improve your quality of life and improve your general health (such as improving body weight and decreasing pain).
- How your body breaks down capecitabine and ruxolitinib when both medicines are given together.
- If ruxolitinib when given with capecitabine has an effect on your disease by analyzing certain biological indicators called “biomarkers”.
A Pilot Study of Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer.
The standard treatment for patients with pancreatic cancer that can be completely removed by surgery is to proceed directly to surgery and to consider additional cancer therapies following surgery. Chemotherapy is often used following surgery and radiation therapy is given in certain cases. There is debate about the effectiveness of standard radiation therapy given following surgery. This study will use a form of radiation therapy, known as stereotactic body radiation therapy (SBRT), given prior to surgery.
Radiation therapy is a type of cancer treatment that uses x-rays to kill cancer cells. SBRT is a form of radiation therapy that uses high doses of radiation given over a short period of time. SBRT is very accurate and is able to spare surrounding normal tissues from the high doses of radiation. SBRT has been successfully used to treat patients with pancreatic cancer in the past, including given before surgery.
A Randomized, Open Label, Phase 2 Trial of Gemcitabine plus Nab-paclitaxel with or without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
The purpose of this study is to evaluate whether FG-3019, an investigational drug, given in combination with the currently approved chemotherapy treatment (gemcitabine and nab-paclitaxel), is safe and tolerable in the treatment of subjects with locally advanced unresectable pancreatic cancer.